Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Diabetes Complications ; 14(5): 242-9, 2000.
Article in English | MEDLINE | ID: mdl-11113685

ABSTRACT

This paper presents the baseline epidemiological data from 5548 patients with type 2 diabetes enrolled in a French observational study that aims to examine the safety, tolerability and use of acarbose as prescribed by general practitioners (GPs). Patients were recruited and monitored by a representative sample of GPs. Recruitment did not depend on a patient's suitability for acarbose treatment. The data revealed that the mean age of the patient population was 63 years, and that more than 50% of patients were over 65 years old. The population was markedly overweight [mean body mass index(BMI): males, 28.4 kg/m(2); females, 29.1 kg/m(2)] and the mean duration of diabetes was 10 (+/-7.3) years. Over 37% of patients had at least one diabetic complication, and the frequency of complications increased with both age and the duration of diabetes. The most frequently reported complications were cardiac (17.8%), vascular (14.5%) and ocular (12%). At recruitment, almost 90% of patients were being treated with oral antidiabetic agents (OADs). Sulphonylureas (74%) and biguanides (50%) were the most commonly prescribed agents. Acarbose was used to treat 17% of patients and 1% were receiving insulin. GPs set glycaemic treatment goals for 44% of patients in the study. Fasting glycaemia was the primary goal for 37% of the total study population, and HbA(1c) levels for 21% of patients. Postprandial glycaemia was generally given as a secondary or tertiary goal. In conclusion, this study provides the most up-to-date epidemiological data for patients with type 2 diabetes in France.


Subject(s)
Acarbose/therapeutic use , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/epidemiology , Hypoglycemic Agents/therapeutic use , Acarbose/adverse effects , Adult , Aged , Databases as Topic , Diabetes Mellitus, Type 2/physiopathology , Diabetic Angiopathies/epidemiology , Diabetic Nephropathies/epidemiology , Diabetic Neuropathies/epidemiology , Diabetic Retinopathy/epidemiology , Family Practice , Female , France/epidemiology , Heart Diseases/epidemiology , Humans , Hypoglycemic Agents/adverse effects , Longitudinal Studies , Male , Middle Aged
2.
Haemophilia ; 6(1): 23-32, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10632738

ABSTRACT

One hundred and 16 patients contributed to an analysis of the impact of the consequences of severe haemophilia A or B (factor levels < 2%) on orthopaedic status, resources consumed in relation to this status and resultant cost, and quality of life as perceived by the patient, using the MOS 36-Item-Short-Form Health Survey (SF-36). This French cross-sectional study involved outpatients regularly attending a haemophilia treatment centre. Data were collected retrospectively over a period of 1 year by the physician of the haemophilia treatment centre. Patients had a mean age of 23, and consisted of 50% students, 25% salaried workers, 17.2% with no professional activity and 7.8% physically impaired; 82.8% of them had type A haemophilia. Mean pain score was 2.5 per patient for the six main joints; 7.7 for the clinical score and 18.8 for the radiological score, with a mean number of bleeds of 16.3 per year per patient. During the year prior to inclusion, and because of their orthopaedic status, 22.4% of patients were hospitalized, 76.7% attended for an outpatient visit and 76.7% required at least one special investigation; 97.4% received replacement therapy, 41.4% required treatment for joint pain and 42.2% orthopaedic equipment. The less affected dimensions were the physical function (76.8 +/- 22. 2) and the social relations (76.1 +/- 23.1). Least good quality of life scores concerned the pain (60.2 +/- 25.2), perception of general health (59.3 +/- 23.1) and vitality (57.8 +/- 19.5) dimensions. The age was a discriminant criterion since quality of life was better in patients of the 18-23 age group for five dimensions. Mean annual treatment costs of a patient with severe haemophilia were determined as 425 762 French francs ($73 029). Loss of production was estimated at a mean of 4609 French francs ($791) per active patient over the course of the year. Results showed indirect evidence of the usefulness of early home treatment.


Subject(s)
Hemophilia A/complications , Hemophilia B/complications , Joint Diseases/etiology , Absenteeism , Activities of Daily Living , Adolescent , Adult , Age Factors , Ankle/diagnostic imaging , Ankle/physiopathology , Arthralgia , Arthrography , Cohort Studies , Costs and Cost Analysis , Cross-Sectional Studies , Data Collection , Efficiency , Elbow Joint/diagnostic imaging , Elbow Joint/physiopathology , France/epidemiology , Hemarthrosis , Hemophilia A/epidemiology , Hemophilia A/therapy , Hemophilia B/epidemiology , Hemophilia B/therapy , Hemorrhage , Humans , Joint Diseases/economics , Joint Diseases/therapy , Knee/diagnostic imaging , Knee/physiopathology , Male , Orthopedic Procedures/economics , Orthopedic Procedures/methods , Pain Measurement , Physical Fitness , Quality of Life , Socioeconomic Factors , Spain/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL
...